The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for ...

QUASAR trial showed Eylea HD matched vision gains of standard Eylea with less frequent dosing. BofA cuts Regeneron price target to $547, maintains Underperform rating. Markets are messy—but the ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate ...

The PFS approval should further drive growth. Sales of Regeneron’s REGN blockbuster ophthalmology drug Eylea have been under ...

Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the Australian biotech to consider its own future. The drug in question is sozinibercept, an inhibitor of vascular ...

Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Eylea HD eye drug. Regeneron on Thursday said the ...

The primary efficacy endpoint of the phase IIb ASPIRE study is demonstrating non-inferiority to Eylea, measured by mean change in Best Corrected Visual Acuity from baseline to the average of weeks ...